Financial Contrast: Haemonetics (NYSE:HAE) vs. Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Femasys and Haemonetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1	0	3	0	2.50
Haemonetics	0	4	6	1	2.73

Femasys currently has a consensus price target of $50.00, indicating a potential upside of 1,916.13%. Haemonetics has a consensus price target of $99.78, indicating a potential downside of 5.23%. Given Femasys’ higher possible upside, analysts clearly believe Femasys is more favorable than Haemonetics.

Valuation & Earnings

This table compares Femasys and Haemonetics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.30 million	9.03	-$18.63 million	($3.53)	-0.70
Haemonetics	$1.35 billion	3.54	$97.31 million	$2.04	51.61

Haemonetics has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Femasys has a beta of -2.07, meaning that its stock price is 307% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

Insider & Institutional Ownership

65.3% of Femasys shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 7.7% of Femasys shares are held by company insiders. Comparatively, 2.1% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Femasys and Haemonetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Haemonetics	7.12%	27.55%	9.65%

Summary

Haemonetics beats Femasys on 12 of the 15 factors compared between the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.